Reilly Thomas Charles
Known title: SVP and CFOCIK: 0001827590
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Tvardi releases preclinical data on STAT3 inhibitor for UC. Tvardi Therapeutics reported new preclinical results that show its STAT3 inhibitor may be effective in treating ulcerative colitis. The data were published in the International Journal of Molecular Sciences. The announcement appeared in recent market round‑ups of health‑care stocks moving in pre‑market and after‑hours sessions.
Transaction History
| AMRN | ▼ Sell | Tax Withholding | 8,209 | $6K | 7/1/2024 | View on chart |
| AMRN | ▲ Buy | Option Exercise | 16,667 | — | 7/1/2024 | View on chart |
| AMRN | ▲ Buy | Option Exercise | 33,333 | — | 6/20/2024 | View on chart |
| AMRN | ▼ Sell | Tax Withholding | 16,417 | $12K | 6/20/2024 | View on chart |
| AMRN | ▲ Buy | Option Exercise | 44,933 | — | 1/31/2024 | View on chart |
| AMRN | ▼ Sell | Tax Withholding | 24,552 | $30K | 1/31/2024 | View on chart |
| AMRN | ▼ Sell | Tax Withholding | 28,325 | $27K | 1/10/2024 | View on chart |
| AMRN | ▲ Buy | Option Exercise | 51,500 | — | 1/10/2024 | View on chart |
| AMRN | ▲ Buy | Option Exercise | 16,667 | — | 7/1/2023 | View on chart |
| AMRN | ▼ Sell | Tax Withholding | 8,209 | $10K | 7/1/2023 | View on chart |
| AMRN | ▲ Buy | Option Exercise | 33,334 | — | 6/20/2023 | View on chart |
| AMRN | ▼ Sell | Tax Withholding | 16,417 | $20K | 6/20/2023 | View on chart |
| TVRD | ▼ Sell | Open Market | 2,044 | $23K | 3/3/2022 | View on chart |
| TVRD | ▲ Buy | Grant | 5,333 | $55K | 2/28/2022 | View on chart |
| TVRD | ▲ Buy | Grant | 20,000 | $0 | 2/25/2022 | View on chart |
| TVRD | ▲ Buy | Grant | 11,170 | $0 | 12/17/2021 | View on chart |
| TVRD | ▼ Sell | Open Market | 1,982 | $28K | 8/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Amarin (AMRN) sees competition as Teva pushes branded drugs
Teva Pharmaceutical announced that branded drugs will be a central part of its growth plan. This focus highlights the competitive environment for other companies with specialty branded products, such as Amarin’s Vascepa. The news may influence market perception of Amarin’s positioning within the branded drug space.
Amarin (AMRN) sees competition as Teva pushes branded drugs. Teva Pharmaceutical announced that branded drugs will be a central part of its growth plan. This focus highlights the competitive environment for other companies with specialty branded products, such as Amarin’s Vascepa. The news may influence market perception of Amarin’s positioning within the branded drug space.